查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球抗體發現人工智慧市場：按技術、解決方案、應用、最終用戶和國家分類的分析和預測（2025-2035 年）
市場調查報告書
商品編碼
1885395

全球抗體發現人工智慧市場：按技術、解決方案、應用、最終用戶和國家分類的分析和預測（2025-2035 年）

AI in Antibody Discovery Market - A Global and Regional Analysis: Focus on Technology, Solution, Application, End User, and Country - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 132 Pages | 商品交期: 1-5個工作天內

價格

全球抗體發現人工智慧市場規模預計將從 2024 年的約 4.104 億美元成長到 2035 年的約 48.431 億美元，複合年成長率約為 24.76%。

儘管傳統抗體藥物研發方法存在諸多局限性，例如高成本、研發週期長、失敗率高等，但人工智慧技術，例如深度學習、生成式人工智慧和抗體特異性大規模語言模型（LLM），正在革新靶點識別、先導化合物發現和最佳化流程，顯著縮短研發週期並提高成功率。

關鍵市場統計數據
預測期 2025-2035
2025 年評估 5.299億美元
2035 年預測 48.431億美元
複合年成長率 24.76%

全球抗體發現人工智慧市場由人工智慧技術提供者、製藥和生物技術公司、受託研究機構(CRO) 以及學術和研究機構組成。各機構正日益利用自主藥物發現平台，以最小的人工干預實現迭代式設計-測試-最佳化循環。生成式人工智慧和多組體學整合正在加速個人化抗體療法的開發，而雲端基礎方案、諮詢服務和本地部署的人工智慧工具則擴大了其可及性。人工智慧Start-Ups與成熟製藥公司之間的策略合作和融資正在加速平台規模化、臨床檢驗和商業化。這些因素共同推動了快速創新，提高了營運效率，並為市場的持續成長奠定了基礎。

基於技術層面，結構預測領域預計將成為市場的主要驅動力，因為它在精確模擬抗體折疊、3D結構和穩定性方面發揮關鍵作用。精準的結構預測能夠幫助製藥和生技公司縮短實驗週期、提高結合親和性並加速有效抗體的發現。其他技術，例如表位定位和從頭設計，透過最佳化候選抗體篩選和提高潛在治療效果，對結構預測有補充作用。

從解決方案來看，人工智慧軟體平台預計將引領市場，因為它提供了一個全面的抗體發現框架，整合了預測建模、生成式人工智慧和濕實驗室相容性。其擴充性、多功能性和加速研究工作流程的能力使其成為全球製藥和生物技術公司的首選。雲端基礎和本地部署工具以及諮詢服務支援其在各種研究環境中的應用。

從應用領域來看，標靶辨識預計將成為市場成長的主要驅動力，因為它為選擇具有治療意義的抗原奠定了基礎。人工智慧驅動的標靶預測能夠提高準確性，縮短發現時間，並提升下游抗體開發的效率。先導化合物的發現和最佳化能夠進一步最佳化候選藥物，進而提高其療效、穩定性和免疫抗原性。

從終端用戶來看，製藥、生物技術和平台開發產業預計將成為市場的主要驅動力，因為這些產業高度採用人工智慧平台來加速研發、最佳化產品線並將新型抗體推向市場。合約研究機構（CRO）和學術機構也做出了重要貢獻，尤其是在早期藥物發現和檢驗。

從區域來看，北美憑藉其完善的醫療基礎設施、大量的研發投入、強力的監管支持以及對抗體發現人工智慧平台的早期應用，在市場中佔據領先地位。歐洲市場較為成熟，擁有強大的合作網路和臨床應用。亞太地區正經歷快速成長，這得益於生物技術領域研發投入的增加、人工智慧新創企業的崛起以及醫療服務可近性的提升。包括拉丁美洲、中東和非洲在內的世界其他地區，由於對醫療保健和生物技術領域的投資不斷增加，也蘊藏著巨大的成長潛力。

本報告調查了全球抗體發現人工智慧市場，並總結了關鍵趨勢、市場影響因素分析、法律制度、研發管線分析、市場規模趨勢和預測、按各個細分市場、地區/主要國家進行的詳細分析、競爭格局以及主要企業的概況。

目錄

執行摘要

範圍和定義

第1章 市場：產業展望

  • 市場概覽
    • 對下一代生物製藥的需求快速成長
    • 利用人工智慧在抗體發現領域實現個人化精準醫療
  • 市場趨勢
    • 採用抗體特異性大規模語言模型（LLM）
    • 策略聯盟和增加投資
  • 監管狀態/合規性
    • 美國
    • EU
    • 亞太地區
    • 其他地區
  • 定價分析
  • 實施策略
    • 人工智慧驅動的生物標記和伴隨診斷整合
    • 利用策略夥伴關係
  • 市場動態
    • 促進因素、挑戰和機會：評估當前和未來的影響
    • 市場促進因素
    • 市場挑戰
    • 市場機遇

第2章 技術

  • 技術摘要
  • 結構預測
  • 表位/互補位預測
  • 從頭抗體設計
  • 親和性成熟與最佳化
  • 其他

第3章答案

  • 解決方案摘要
  • 人工智慧軟體平台
  • 雲端基礎的解決方案
  • 本地部署人工智慧工具
  • 諮詢和整合服務

第4章 應用

  • 使用摘要
  • 目標識別
  • 先導抗體發現
  • 先導藥物最適化
  • 其他

第5章 最終用戶

  • 最終用戶摘要
  • 製藥、生物技術和平台開發公司
  • 合約研究組織（CRO）
  • 學術研究機構
  • 其他

第6章 區域

  • 區域摘要
  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區
    • 區域概覽
    • 市場成長促進因素
    • 市場問題
    • 市場規模及預測
    • 按國家/地區

第7章 市場：競爭基準化分析與公司概況

  • 關鍵策略和發展（按公司分類）
  • 公司簡介
    • LabGenius Therapeutics
    • BigHat Biosciences, Inc.
    • Generate Biomedicines, Inc.
    • InveniAI LLC
    • Antiverse
    • EVQLV Inc.
    • Chai Discovery Inc.
    • MAbSilico
    • Cradle Bio BV
    • Alloy Therapeutics, Inc.

第8章調查方法

Product Code: BHL3201SA

This report can be delivered within 1 working day.

Global AI in antibody discovery market: Industry Overview

The global AI in antibody discovery market was valued at approximately $410.4 million in 2024 and is projected to grow $4,843.1 million by 2035, at a CAGR of around 24.76%. Growth is driven by the limitations of conventional antibody discovery methods, which are costly, time-intensive, and prone to high failure rates. AI-enabled technologies, including deep learning, generative AI, and antibody-specific large language models (LLMs), are transforming the process of target identification, lead discovery, and optimization, significantly reducing development timelines and improving success rates.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$529.9 Million
2035 Forecast$4,843.1 Million
CAGR24.76%

The global AI in antibody discovery market encompasses AI technology providers, pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic and research institutions. Organizations are increasingly leveraging autonomous discovery platforms to enable iterative design-test-optimize cycles with minimal human intervention. Generative AI and multi-omics integration are facilitating personalized antibody therapeutics, while cloud-based solutions, consulting services, and on-premise AI tools expand accessibility. Strategic collaborations and funding between AI startups and established pharmaceutical companies accelerate platform scale-up, clinical validation, and commercialization. Collectively, these factors are driving rapid innovation, improving operational efficiency, and positioning the market for sustained growth.

Global AI in Antibody Discovery Market Lifecycle Stage

The global AI in antibody discovery market is in the expansion phase, characterized by rapid adoption, substantial investment, and strategic collaborations between innovative startups and established pharmaceutical companies. High attrition rates and the escalating costs associated with traditional antibody discovery have catalysed the transition toward AI-enabled platforms. Integration of AI with wet lab experimentation enhances efficiency, reduces failure rates, and supports iterative optimization cycles. The use of antibody-specific LLMs improves predictive accuracy for structure, binding affinity, and immunogenicity, increasing the probability of successful antibody candidates.

Despite these supporting factors, several challenges remain, including data bottlenecks from limited high-quality datasets and validation gaps requiring experimental confirmation. However, the market presents substantial growth opportunities through generative AI, autonomous discovery platforms, and multi-omics integration, enabling the design of novel antibodies and personalized therapeutics. Expansion into emerging regions with increasing healthcare investments, supportive regulatory frameworks, and growing R&D initiatives further positions the market for sustained growth. Stakeholders are increasingly focusing on technological advancement, strategic alliances, and scalable solutions to optimize antibody discovery efficiency and maintain a competitive advantage.

Market Segmentation:

Segmentation 1: By Technology

  • Structure Prediction
  • Epitope/Paratope Prediction
  • De Novo Antibody Design
  • Affinity Maturation & Optimization
  • Others

Structure Prediction is expected to lead the market due to its critical role in accurately modelling antibody folding, 3D structures, and stability. By enabling precise structural predictions, pharmaceutical and biotechnology companies can reduce experimental cycles, improve binding affinity, and accelerate the discovery of effective antibodies. Other technologies, such as epitope mapping and de novo design, complement structure prediction by refining candidate selection and optimizing therapeutic potential.

Segmentation 2: By Solution

  • AI Software Platforms
  • Cloud-Based Solutions
  • On-Premise AI Tools
  • Consulting & Integration Services

AI Software Platforms are projected to lead the market as they provide comprehensive frameworks for antibody discovery, integrating predictive modelling, generative AI, and wet lab compatibility. Their scalability, versatility, and ability to accelerate research workflows make them the preferred choice for pharmaceutical and biotechnology companies globally. Cloud-based and on-premise tools, along with consulting services, support adoption across diverse research settings.

Segmentation 3: By Application

  • Target Identification
  • Lead Antibody Discovery
  • Lead Optimization
  • Others

Target Identification is expected to lead the application segment because it is fundamental for selecting therapeutically relevant antigens. AI-driven target prediction improves precision, reduces discovery timelines, and enhances downstream antibody development efficiency. Lead discovery and optimization further refine candidates to improve efficacy, stability, and immunogenicity.

Segmentation 4: By End User

  • Pharmaceutical, Biotechnology, and Platform Developing Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Others

Pharmaceutical, biotechnology, and platform developing companies are expected to lead the market due to their high adoption of AI-enabled platforms to accelerate R&D, optimize pipelines, and bring novel antibodies to market. CROs and academic institutes also contribute significantly, particularly in early-stage discovery and validation.

Segmentation 5: By Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest-of-the-World

North America leads the market with a well-established healthcare infrastructure, significant R&D investment, strong regulatory support, and early adoption of AI platforms in antibody discovery. Europe represents a mature market with robust collaborations and clinical adoption. The Asia-Pacific region is witnessing rapid growth driven by increasing biotech R&D, emerging AI companies, and improving healthcare access. Rest-of-the-world regions, including Latin America, the Middle East, and Africa, offer additional growth opportunities due to rising investments in healthcare and biotechnology.

Demand - Drivers and Limitations

Demand drivers for the global AI in antibody discovery market:

  • High attrition rates and costs associated with traditional antibody discovery methods
  • AI integration with wet labs accelerating antibody discovery

Limitations for the global AI in antibody discovery market:

  • Data bottlenecks hindering innovation in AI-enabled antibody discovery
  • Validation gap in AI-driven antibody discovery

How can this report add value to an organization?

Product/Innovation: This report enables organizations to identify high-value opportunities in global AI in antibody discovery market, including generative AI, autonomous platforms, and antibody-specific LLMs. It guides R&D investment decisions, pipeline optimization, and technology adoption, helping companies prioritize initiatives that accelerate lead identification and antibody optimization. The report provides actionable insights on platform scalability, wet lab integration, and predictive modelling accuracy, allowing stakeholders to reduce development costs, improve success rates, and maintain a competitive advantage in the rapidly evolving antibody discovery market.

Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across technology, solution, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive global landscape.

Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the AI-driven antibody discovery ecosystem.

Key Market Players and Competitive Landscape

The global AI in antibody discovery market is characterized by a highly competitive and evolving landscape, with participation from innovative biotechnology startups, established pharmaceutical companies, and AI technology providers. Key players include:

  • LabGenius Therapeutics
  • BigHat Biosciences, Inc.
  • Generate: Biomedicines, Inc.
  • Alloy Therapeutics, Inc.
  • InveniAI LLC
  • Antiverse Ltd.
  • EVQLV, Inc.
  • Chai Discovery, Inc.
  • Cradle Bio B.V.
  • MAbsillco

Competitive benchmarking highlights mergers and acquisitions, funding activities, licensing deals, and collaborations with pharmaceutical organizations, reflecting the growing emphasis on innovation and speed-to-market. Companies are evaluated based on market presence, technological capabilities, strategic initiatives, and product portfolios. Detailed company profiles cover target end users, technological focus areas, and expert analyst perspectives, providing stakeholders with actionable insights into investment opportunities, market positioning, and strategic growth pathways. This intelligence enables organizations to effectively align their R&D and commercialization strategies with emerging market dynamics of the global AI in antibody discovery market.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

  • 1.1 Market Overview
    • 1.1.1 Surging Demand for Next-Generation Biologics
    • 1.1.2 Leveraging AI for Personalized Precision Medicine in Antibody Discovery
  • 1.2 Market Trends
    • 1.2.1 Adoption of Antibody-Specific Large Language Models (LLMs)
    • 1.2.2 Increasing Strategic Collaborations and Investments
  • 1.3 Regulatory Landscape / Compliance
    • 1.3.1 U.S.
    • 1.3.2 E.U.
      • 1.3.2.1 France
      • 1.3.2.2 Italy
    • 1.3.3 Asia-Pacific
      • 1.3.3.1 China
      • 1.3.3.2 Japan
    • 1.3.4 Rest-of-the-World
      • 1.3.4.1 Brazil
      • 1.3.4.2 U.A.E.
  • 1.4 Pricing Analysis
  • 1.5 Implementation Strategies
    • 1.5.1 AI-Driven Biomarker and Companion Diagnostic Integration
    • 1.5.2 Leveraging Strategic Partnerships
  • 1.6 Market Dynamics
    • 1.6.1 Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
    • 1.6.2 Market Drivers
      • 1.6.2.1 High Attrition Rates and Costs Associated with Traditional Antibody Discovery Methods
      • 1.6.2.2 AI Integration with Wet Labs Accelerating Antibody Discovery
    • 1.6.3 Market Challenges
      • 1.6.3.1 Data Bottlenecks Hindering Innovation in AI-Enabled Antibody Discovery
      • 1.6.3.2 Validation Gap in AI-Driven Antibody Discovery
    • 1.6.4 Market Opportunities
      • 1.6.4.1 Generative AI and Deep Learning for Novel Antibody Design
      • 1.6.4.2 Autonomous Discovery Platforms and AI Agents
      • 1.6.4.3 Establishing Antibody Data Foundries and Collaborative Networks

2 Technology

  • 2.1 Technology Summary
  • 2.2 Structure Prediction
  • 2.3 Epitope/Paratope Prediction
  • 2.4 De Novo Antibody Design
  • 2.5 Affinity Maturation and Optimization
  • 2.6 Others

3 Solution

  • 3.1 Solution Summary
  • 3.2 AI Software Platforms
  • 3.3 Cloud-Based Solutions
  • 3.4 On-Premise AI Tools
  • 3.5 Consulting and Integration Services

4 Application

  • 4.1 Application Summary
  • 4.2 Target Identification
  • 4.3 Lead Antibody Discovery
  • 4.4 Lead Optimization
  • 4.5 Others

5 End User

  • 5.1 End User Summary
  • 5.2 Pharmaceutical, Biotechnology, and Platform Developing Companies
  • 5.3 Contract Research Organizations (CROs)
  • 5.4 Academic and Research Institutes
  • 5.5 Others

6 Region

  • 6.1 Regional Summary
  • 6.2 North America
    • 6.2.1 Regional Overview
    • 6.2.2 Driving Factors for Market Growth
    • 6.2.3 Factors Challenging the Market
    • 6.2.4 Market Sizing and Forecast
    • 6.2.5 By Country
      • 6.2.5.1 U.S.
    • 6.2.6 Market Sizing and Forecast
      • 6.2.6.1 Canada
    • 6.2.7 Market Sizing and Forecast
  • 6.3 Europe
    • 6.3.1 Regional Overview
    • 6.3.2 Driving Factors for Market Growth
    • 6.3.3 Factors Challenging the Market
    • 6.3.4 Market Sizing and Forecast
    • 6.3.5 By Country
      • 6.3.5.1 U.K.
    • 6.3.6 Market Sizing and Forecast
      • 6.3.6.1 Germany
    • 6.3.7 Market Sizing and Forecast
      • 6.3.7.1 France
    • 6.3.8 Market Sizing and Forecast
      • 6.3.8.1 Italy
    • 6.3.9 Market Sizing and Forecast
      • 6.3.9.1 Spain
    • 6.3.10 Market Sizing and Forecast
      • 6.3.10.1 Rest-of-Europe
    • 6.3.11 Market Sizing and Forecast
  • 6.4 Asia-Pacific
    • 6.4.1 Regional Overview
    • 6.4.2 Driving Factors for Market Growth
    • 6.4.3 Factors Challenging the Market
    • 6.4.4 Market Sizing and Forecast
    • 6.4.5 By Country
      • 6.4.5.1 Japan
    • 6.4.6 Market Sizing and Forecast
      • 6.4.6.1 China
    • 6.4.7 Market Sizing and Forecast
      • 6.4.7.1 India
    • 6.4.8 Market Sizing and Forecast
      • 6.4.8.1 Australia
    • 6.4.9 Market Sizing and Forecast
      • 6.4.9.1 South Korea
    • 6.4.10 Market Sizing and Forecast
      • 6.4.10.1 Rest-of-the-Asia-Pacific
    • 6.4.11 Market Sizing and Forecast
  • 6.5 Rest-of-the-World
    • 6.5.1 Market Sizing and Forecast

7 Markets - Competitive Benchmarking & Company Profiles

  • 7.1 Key Strategies and Developments (by Company)
    • 7.1.1 Funding Activities
    • 7.1.2 Mergers and Acquisitions
    • 7.1.3 Product Launches
    • 7.1.4 Partnerships, Collaborations, and Business Expansions
  • 7.2 Company Profiles
    • 7.2.1 LabGenius Therapeutics
      • 7.2.1.1 Overview
      • 7.2.1.2 Top Products/Product Portfolio
      • 7.2.1.3 Top Competitors
      • 7.2.1.4 Target Customers
      • 7.2.1.5 Key Personal
      • 7.2.1.6 Analyst View
    • 7.2.2 BigHat Biosciences, Inc.
      • 7.2.2.1 Overview
      • 7.2.2.2 Top Products/Product Portfolio
      • 7.2.2.3 Top Competitors
      • 7.2.2.4 Target Customers
      • 7.2.2.5 Key Personal
      • 7.2.2.6 Analyst View
    • 7.2.3 Generate Biomedicines, Inc.
      • 7.2.3.1 Overview
      • 7.2.3.2 Top Products/Product Portfolio
      • 7.2.3.3 Top Competitors
      • 7.2.3.4 Target Customers
      • 7.2.3.5 Key Personal
      • 7.2.3.6 Analyst View
    • 7.2.4 InveniAI LLC
      • 7.2.4.1 Overview
      • 7.2.4.2 Top Products/Product Portfolio
      • 7.2.4.3 Top Competitors
      • 7.2.4.4 Target Customers
      • 7.2.4.5 Key Personal
      • 7.2.4.6 Analyst View
    • 7.2.5 Antiverse
      • 7.2.5.1 Overview
      • 7.2.5.2 Top Products/Product Portfolio
      • 7.2.5.3 Top Competitors
      • 7.2.5.4 Target Customers
      • 7.2.5.5 Key Personal
      • 7.2.5.6 Analyst View
    • 7.2.6 EVQLV Inc.
      • 7.2.6.1 Overview
      • 7.2.6.2 Top Products/Product Portfolio
      • 7.2.6.3 Top Competitors
      • 7.2.6.4 Target Customers
      • 7.2.6.5 Key Personal
      • 7.2.6.6 Analyst View
    • 7.2.7 Chai Discovery Inc.
      • 7.2.7.1 Overview
      • 7.2.7.2 Top Products/Product Portfolio
      • 7.2.7.3 Top Competitors
      • 7.2.7.4 Target Customers
      • 7.2.7.5 Key Personal
      • 7.2.7.6 Analyst View
    • 7.2.8 MAbSilico
      • 7.2.8.1 Overview
      • 7.2.8.2 Top Products/Product Portfolio
      • 7.2.8.3 Top Competitors
      • 7.2.8.4 Target Customers
      • 7.2.8.5 Key Personal
      • 7.2.8.6 Analyst View
    • 7.2.9 Cradle Bio B.V.
      • 7.2.9.1 Overview
      • 7.2.9.2 Top Products/Product Portfolio
      • 7.2.9.3 Top Competitors
      • 7.2.9.4 Target Customers
      • 7.2.9.5 Key Personal
      • 7.2.9.6 Analyst View
    • 7.2.10 Alloy Therapeutics, Inc.
      • 7.2.10.1 Overview
      • 7.2.10.2 Top Products/Product Portfolio
      • 7.2.10.3 Top Competitors
      • 7.2.10.4 Target Customers
      • 7.2.10.5 Key Personal
      • 7.2.10.6 Analyst View

8 Research Methodology

  • 8.1 Data Sources
    • 8.1.1 Primary Data Sources
    • 8.1.2 Secondary Data Sources
    • 8.1.3 Data Triangulation
  • 8.2 Market Estimation and Forecast

List of Figures

  • Figure 1: AI in Antibody Discovery Market (by Scenario), $Million, 2024, 2030, and 2035
  • Figure 2: Global Market Snapshot, 2024
  • Figure 3: AI in Antibody Discovery Market, $Million, 2024 and 2035
  • Figure 4: AI in Antibody Discovery Market (by Technology), $Million, 2024, 2030, and 2035
  • Figure 5: AI in Antibody Discovery Market (by Solution), $Million, 2024, 2030, and 2035
  • Figure 6: AI in Antibody Discovery Market (by Application), $Million, 2024, 2030, and 2035
  • Figure 7: AI in Antibody Discovery Market (by End User), $Million, 2024, 2030, and 2035
  • Figure 8: AI application across the Antibody Discovery Workflow
  • Figure 9: Advanced Antibody Design and Optimization
  • Figure 10: AI in Antibody Discovery Market (Structure Prediction), $Million, 2024-2035
  • Figure 11: AI in Antibody Discovery Market (Epitope/Paratope Prediction), $Million, 2024-2035
  • Figure 12: AI in Antibody Discovery Market (De Novo Antibody Design), $Million, 2024-2035
  • Figure 13: AI in Antibody Discovery Market (Affinity Maturation and Optimization), $Million, 2024-2035
  • Figure 14: AI in Antibody Discovery Market (Others), $Million, 2024-2035
  • Figure 15: AI in Antibody Discovery Market (AI Software Platforms), $Million, 2024-2035
  • Figure 16: AI in Antibody Discovery Market (Cloud-Based Solutions), $Million, 2024-2035
  • Figure 17: AI in Antibody Discovery Market (On-Premise AI Tools), $Million, 2024-2035
  • Figure 18: AI in Antibody Discovery Market (Consulting and Integration Services), $Million, 2024-2035
  • Figure 19: AI in Antibody Discovery Market (Target Identification), $Million, 2024-2035
  • Figure 20: AI in Antibody Discovery Market (Lead Antibody Discovery), $Million, 2024-2035
  • Figure 21: AI in Antibody Discovery Market (Lead Optimization), $Million, 2024-2035
  • Figure 22: AI in Antibody Discovery Market (Others), $Million, 2024-2035
  • Figure 23: AI in Antibody Discovery Market (Pharmaceutical, Biotechnology, and Platform Developing Companies), $Million, 2024-2035
  • Figure 24: AI in Antibody Discovery Market (Contract Research Organizations (CROs), $Million, 2024-2035
  • Figure 25: AI in Antibody Discovery Market (Academic and Research Institutes), $Million, 2024-2035
  • Figure 26: AI in Antibody Discovery Market (Others), $Million, 2024-2035
  • Figure 27: North America AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 28: U.S. AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 29: Canada AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 30: Europe AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 31: U.K. AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 32: Germany AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 33: France AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 34: Italy AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 35: Spain AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 36: Rest-of-Europe AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 37: Asia-Pacific AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 38: Japan AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 39: China AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 40: India AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 41: Australia AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 42: South Korea AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 43: Rest-of-Asia-Pacific AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 44: Rest-of-the-World AI in Antibody Discovery Market, $Million, 2024-2035
  • Figure 45: Data Triangulation
  • Figure 46: Top-Down and Bottom-Up Approach
  • Figure 47: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Competitive Landscape Analysis
  • Table 3: Companies Involved in Funding and Collaboration
  • Table 4: Leading Platforms and their Pricing Model
  • Table 5: AI in Antibody Discovery Market (by Region), $Million, 2024-2035